Vor Biopharma
80 hedge funds and large institutions have $717M invested in Vor Biopharma in 2026 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 9 closing their positions.
289% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 9
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
143.14% more ownership
Funds ownership: 245.39% → 388.53% (+143%)
116% more capital invested
Capital invested by funds: $332M → $717M (+$385M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
45% more funds holding
Funds holding: 55 → 80 (+25)
73% less call options, than puts
Call options by funds: $919K | Put options by funds: $3.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$80M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$16.3M |
| 3 |
VA
VR Adviser
New York
|
+$15.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.5M |
| 5 |
CP
Caligan Partners
New York
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.02M |
| 3 |
FCM
Findell Capital Management
New York
|
-$3.02M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.13M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.25M |
VOR Hedge Fund Activity: Q1 2026 in Review
80 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2026, worth a combined $717M — up 116% from $332M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new VOR positions and 9 closed out — a net gain of 26 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $80M. The largest seller was Fidelity Investments, cutting an estimated $13.9M.
- 80 institutional investors held Vor Biopharma (VOR) as of Q1 2026, up from 55 in Q4 2025.
- Funds reported $717M of Vor Biopharma stock for Q1 2026, up 116% quarter-over-quarter.
- 35 funds opened new Vor Biopharma positions in Q1 2026 and 9 closed out, a net change of +26 holders.
- The largest Vor Biopharma buyer in Q1 2026 was TCG Crossover Management, an estimated $80M added.
- The largest Vor Biopharma seller in Q1 2026 was Fidelity Investments, an estimated $13.9M sold.
Based on aggregated 13F filings for Q1 2026.